Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1
| Autor: | Visco V, Dolecek C, Denépoux S, Le Mao J, Guret C, Rousset F, Mt, Guinnepain, Kraft D, Rudolf Valenta, Weyer A, Banchereau J, Labecque S |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1996 |
| Předmět: |
Immunology
Antibodies Monoclonal chemical and pharmacologic phenomena hemic and immune systems Allergens Antigens Plant Cross Reactions Immunoglobulin E Binding Competitive Histamine Release Basophils Adjuvants Immunologic Antibody Specificity Immunoglobulin G Immunology and Allergy Humans Pollen Binding Sites Antibody Epitope Mapping Plant Proteins |
| Zdroj: | Europe PubMed Central |
| ISSN: | 1550-6606 0022-1767 |
| Popis: | Birch pollen allergy is a very frequent pathology in Europe and North America. More than 95% of the tree pollen allergic patients display IgE reactivity against Bet v 1, the major birch pollen allergen. Starting with PBL from a patient desensitized by immunotherapy, we have generated five B cell lines (BAB1 to BAB5) that secrete human IgG mAbs of high affinity for Bet v 1. Although competition studies indicated that these human IgG mAb recognized different epitopes, broad cross-reactivity was found with Bet v 1 homologous allergens present in tree pollens and plant-derived foods. When tested for interference with allergic patients' IgE, BAB1 inhibited (by 80-100%) the binding of IgE to nitrocellulose-blotted Bet v 1, while BAB2 enhanced it. The biologic significance of the ability of BAB1 to interfere with patients' IgE binding is indicated by the finding that BAB1 completely inhibited Bet v 1-induced histamine release from allergic patients' basophils. Allergen-specific human IgG mAbs such as BAB1, which presents high blocking activity in both immunochemical and cellular IgE competition experiments, might have therapeutical application. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|